The U.S. biobanking market size surpassed USD 8.33 billion in 2025 and is predicted to reach around USD 19.36 billion by 2035, registering a CAGR of 8.8% from 2026 to 2035. The market is mainly fueled by a surge in investments in precision medicine, genomics research, and the growing need for personalized therapies.

U.S. Biobanking Market Statical Scope

This market is essential for the progress of modern medicine, aiding personalized medicine , speeding up drug discovery, and enhancing pandemic readiness. By gathering, preserving, and managing high-quality biospecimens, these biobanks help researchers find new disease biomarkers and create targeted therapies. The market is expanding quickly due to automation and increased funding in chronic disease research.

Biobanks are vital for storing and supplying specimens necessary for COVID-19 and other infectious disease studies, diagnostics, and vaccine creation. The market is shifting from basic storage to sophisticated, automated systems that improve accuracy and efficiency, making them key to biomedical infrastructure. Key players in this market include Thermo Fisher Scientific Inc., Labcorp, and Cryoport.

U.S. Biobanking Market Share, By Sample Storage, 2025 (%)

• Blood - Holding a 45.00% share, the blood segment is the leading and vital part of the U.S. biobanking market. This is mainly due to the necessity of blood-derived samples for genomic, proteomic, and longitudinal studies. Its significance arises from the high demand for easily collected samples that produce extensive data for non-cancerous diseases.
• Cells & Tissues - With a 35.00% share, the Cells & Tissues segment plays a crucial role in the U.S. biobanking market, due to its essential function in oncology research, biomarker validation, and histopathology. This sector is experiencing rapid growth driven by the pressing need for samples in personalized medicine and regenerative therapies.

U.S. Biobanking Market Share, By Application, 2025 (%)

• Regenerative Medicines - Holding a 50.00% share, the regenerative medicines segment is the most important growth factor in the U.S. biobanking market. Its significance comes from its ability to transform biobanks from mere storage facilities into active, high-value repositories for personalized medicine, advanced therapies, and curative treatments for previously untreatable chronic diseases.
• Life Science - With a 40.00% share, the life science segment is an important application in the U.S. biobanking market, as it supplies the essential high-quality biospecimens required for pharmaceutical R&D, genomic research, and precision medicine initiatives. By aiding in the identification of new biomarkers and speeding up drug discovery, this segment creates a strong demand for stored samples.

U.S. Biobanking Market Share, By Settings, 2025 (%)

• Academic Medical Institutions - The Academic Medical Institutions segment holds a dominant 56.00% share, serving as a key part of the U.S. biobanking market. It plays a vital role in driving biomedical innovation, sample collection, and advanced research. This segment includes research universities and academic hospitals, which excel in merging patient care with rigorous research efforts.
• Pharmaceutical & Biotechnological Companies - The pharmaceutical and biotechnological companies segment accounts for 44.00% of the market share, making it the largest end-user in the U.S. biobanking sector. Due to the pressing demand for high-quality, annotated biospecimens that are essential for speeding up drug discovery, clinical trials, and precision medicine, the segment plays a key role.

Top Companies in the U.S. Biobanking Market

• Thermo Fisher Scientific Inc.
• Tecan Trading AG
• QIAGEN
• Hamilton Company
• Brooks Life Sciences
• TTP Labtech
• VWR International, LLC.
• Promega Corporation
• Worthington Industries
• BD
• Merck KGaA
• Biokryo GmbH
• Cell&Co BioServices
• RUCDR Infinite Biologics
• Modul-Bio

Segments Covered in the Report

By Sample Storage

• Blood
• Cells & Tissues
• Others

By Application

• Regenerative Medicines
• Life Science
• Others

By Settings

• Academic Medical Institutions
• Pharmaceutical & Biotechnological Companies